← Leaderboards
Robert L Coffman
Dynavax Technologies Corporation
$6,700,309
Attributed
$6,700,309
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,700,309 · 10
By mechanism
U19$1,959,287 · 1
R44$1,811,029 · 1
U01$1,701,721 · 1
P51$616,076 · 5
R43$612,196 · 2
Top collaborators
No co-investigators on record.
Most similar at Dynavax Technologies Corporation
Same institution · by research overlap
- Franck Barrat$2,920,339
- Cristiana Guiducci$1,613,878
- Albert F Candia$1,123,962
- Annette Hillebrand$595,825
Others in their field
Top investigators on “Oligonucleotides”
- Monte Westerfield · University Of Oregon$78,765,009
- David Heimbrook · Leidos Biomedical Research, Inc.$73,743,088
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Randall J Bateman · Washington University$63,044,576
- Larry Arthur$39,727,172
- Ronald Wayne Davis · Stanford University$38,345,338
Research focus
OligonucleotidesDoseResponseImmune SystemPlayCell TypeBaseCellsVirusSeriesFrequencies (Time Pattern)MonkeysImmunizationFundingClinical TrialsGrantAgonistAntigensLungNatural ImmunityLigandsPersonsControlled StudyAdjuvant
Grant awards (18)
Systems Biology Analysis of the Response to 2 HBV vaccines: Heplisav and Engerix$147,455
U19 · FY2014 · AI · contact PI
Systems Biology Analysis of the Response to 2 HBV vaccines: Heplisav and Engerix$760,628
U19 · FY2013 · AI · contact PI
Screening for Inhibitors of TLR8 for Treatment of Rheumatoid Arthritis$105,088
R43 · FY2013 · AI · contact PI
Systems Biology Analysis of the Response to 2 HBV vaccines: Heplisav and Engerix$656,879
U19 · FY2012 · AI · contact PI
Screening for Inhibitors of TLR8 for Treatment of Rheumatoid Arthritis$299,830
R43 · FY2012 · AI · contact PI
Systems Biology Analysis of the Response to 2 HBV vaccines: Heplisav and Engerix$394,325
U19 · FY2011 · AI · contact PI
Development of an inhibitory oligonucleotide for the treatment of lupus$932,510
R44 · FY2009 · AI · contact PI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$106,670
P51 · FY2009 · RR · contact PI
Development of an inhibitory oligonucleotide for the treatment of lupus$878,519
R44 · FY2008 · AI · contact PI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$81,333
P51 · FY2008 · RR · contact PI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$82,027
P51 · FY2007 · RR · contact PI
Development of an Inhibitory Oligonucleotide for the Treatment of Lupus$207,278
R43 · FY2006 · AI · contact PI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$74,514
P51 · FY2006 · RR · contact PI
Immunostimulatory DNA Priming of Lung Innate Immunity$202,329
U01 · FY2005 · AI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$83,177
P51 · FY2005 · RR
Immunostimulatory DNA Priming of Lung Innate Immunity$759,577
U01 · FY2004 · AI
IMMUNOSTIMULATORY DNA PRIMING OF LUNG INNATE IMMUNITY$188,355
P51 · FY2004 · RR
Immunostimulatory DNA Priming of Lung Innate Immunity$739,815
U01 · FY2003 · AI